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Abstract
Management of sudden cardiac death (SCD) is undergoing radical change in direction. It is
becoming increasingly appreciated that besides depressed left ventricular systolic function and
the conventional risk stratification tools, new markers for plaque vulnerability, enhanced
thrombogenesis, specific genetic alterations of the autonomic nervous system, cardiac sarco-
lemmal and contractile proteins, and familial clustering  may better segregate patients with
atherosclerotic coronary artery disease (CAD) who are at high risk of SCD from those who may
suffer from nonfatal ischemic events. Better understanding of pathophysiologic processes such
as post-myocardial infarction remodeling, the transition from compensated hypertrophy to
heart failure, and the increased cardiovascular risk of CAD in the presence of diabetes or even
a pre-diabetic state will help to improve both risk stratification and management. The rapidly
developing fields of microchips technology, and proteomics may allow rapid and cost-effective
mass screening of multiple risk factors for SCD. The ultimate goal is not only to change the
current direction of management strategy of SCD away from increased ICD utilization, but to
identify novel methods for risk stratification, risk modification, and prevention of SCD that
could be applied to the general public at large. (Cardiol J 2010; 17, 1: 4–10)
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Coronary artery disease and
sudden cardiac death cascade (Fig. 1)
The majority of sudden cardiac death (SCD)
occurs in patients with atherosclerotic coronary
artery disease (CAD) (65–85%) [1]. However, there
is considerable evidence that traditional markers of
CAD, such as hypertension, obesity, smoking, dia-
betes, and lipid abnormalities, are not specific
enough to identify patients at high risk for SCD [2].
Patients with similar risk factors for CAD may suf-
fer from SCD or nonfatal ischemic events. The rea-
son for this difference is not clear. Exciting evidence
has been made in recent years in genetic studies of
CAD and myocardial infarction (MI). One disease-
-causing gene for CAD and MI has been identified
as MEF2A, which is located on chromosome
15q26.3 and encodes for a transcriptional factor with
high level of expression in coronary endothelium
[3]. Approximately 1% to 2% of CAD patients may
carry an MEF2A mutation. Several other suscepti-
bility genes have been identified using genome-
-wide association studies or genome-wide linkage
studies [3]. There is a new understanding of the
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cascade that relates the distal events of atheroscle-
rosis to the proximal event of SCD. New risk mark-
ers for SCD in CAD are likely to cluster under fac-
tors that may directly facilitate the development of
acute coronary syndromes, specifically those fac-
tors that may facilitate transient triggering events,
including plaque rupture, enhanced thrombogenesis,
and coronary artery spasm [4, 5]. There is signifi-
cant data showing correlation between SCD and
1) markers of plaque vulnerability, such as herita-
ble alterations of specific matrix metalloproteinas-
es [6]; 2) markers of enhanced thrombogenesis,
such as increased D-dimer, increased apo-B, and de-
creased apo-A1 [7]; polymorphism in platelet glyc-
oprotein receptors [8]; 3) genetic variations that
predispose to vasospasm, such as variations in the
vascular endothelial nitric oxide synthetase (eNOS)
system [9, 10]; and 4) markers of inflammatory re-
sponse, such as C-reactive protein [11].
Diabetes, coronary artery disease,
and risk of sudden cardiac death
Cardiovascular disease is the leading cause of
death in individuals with type 2 diabetes, which af-
fects about 15 million Americans [12]. This is com-
patible with the “common soil” hypothesis, which
postulates that both diabetes and cardiovascular
disease have common genetic and environmental
antecedents, i.e., “they spring from the same soil”
[13]. There is evidence that diabetes is a significant
risk factor for SCD but not for nonfatal MI [14]. The
increased risk of death and mortality rates associa-
ted with diabetes are compounded by the fact that
many diabetic individuals are unaware that they
suffer from the metabolic syndrome. There is strong
evidence that the elevated risk for cardiovascular
disease starts to increase long before the onset of
clinical diabetes, confirming the so-called “ticking
clock” hypothesis [15]. The incidence of impaired
glucose tolerance and diabetes may be as high as
39% and 31%, respectively, in patients admitted
with acute MI [16]. Recent studies have document-
ed increased inflammation, neovascularization, and
intraplaque hemorrhage in human diabetic athero-
sclerosis [17]. Because of vulnerability of diabetic
patients to plaque rupture and acute MI, a question
of considerable importance is whether patients with
CAD, diabetes or prediabetes, and relatively pre-
served left ventricular (LV) systolic function (left
Figure 1. Coronary artery disease (CAD) and sudden cardiac death (SCD) cascade; EP — electrophysiological;
ICD — implantable cardioverter defibrillator; MI — myocardial infarction; VT/VF — ventricular tachycardia/ventricular
fibrillation.
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ventricular ejection fraction — LVEF ≥ 35%) can
benefit from primary implantable cardioverter-
-defibrillator (ICD) prophylaxis.
The autonomic system and enhanced
susceptibility to sudden cardiac death
Autonomic neural influences, especially in-
creased adrenergic and decreased cholinergic ac-
tivity, can modulate the susceptibility to SCD fol-
lowing MI. Resting heart rate has been shown to
be an independent risk factor for SCD in middle-
aged men [18]. There are data showing the herita-
bility of heart rate variation [19]. Adrenergic ago-
nists are known to trigger ventricular arrhythmias,
and their circulating levels have similar diurnal pat-
terns as SCD events [20]. Genetic polymorphism
of b-adrenergic receptors have been associated with
increased susceptibility to SCD in ischemic deart
disease [21]. The association between plasma non-
esterified fatty acids and SCD may be related to
increased adrenergic tone or the effect on ion chan-
nel and transporters [22]. Further, mental stress
was found to be associated with lateralization of mid
brain activity resulting in imbalanced activity in
right and left cardiac sympathetic nerves and in-
creased dispersion of repolarization, predisposing
to arrhythmia [23]. Recently a third type of b-adren-
ergic receptors, b-3 adrenergic receptors were
found in the human heart [24]. In both failing and
post-MI myocardium, b-3 adrenergic receptors
stimulation may have protective effects against
b-1 and b-2 catecholaminergic stimulation [25]. This
makes b-3 adrenergic receptors a very attractive tar-
get for pharmacologic therapy of cardiac arrhythmias
related to cardiac sympathetic nerve stimulation.
Cardiac gene mutations and enhanced
susceptibility to sudden cardiac death
There is compelling evidence that a genetic
mechanism may increase a patient susceptibility to
SCD following MI. Subtle genetic variations such
as single nucleotide polymorphisms can influence
the phenotypic expression of low penetrance ion
channel mutations and increased the propensity to
VA and SCD [26]. One clue of the role that genetic
factors may play in SCD has been evidence of “fam-
ily clustering” of SCD victims. Population studies
have reported that familial clustering of SCD events
is an important independent factor in multifactorial
analyses of SCD risk. This may be related to shared
environmental or genetically transmittable abnor-
malities. Evidence favoring a focus on genetic fac-
tors was presented in epidemiologic studies that
suggested not only that familial risks for SCD ap-
pear substantial, but that they are statistically dis-
tinct and separable from familial risks of MI [27–
–30]. In one study parental history of SCD increased
the relative risk of SCD to 1.8 after adjustment for
conventional CAD risk factors, but it did not ele-
vate the risk for deaths coded as non-sudden. In
a small subset in which there was a history of both
maternal and paternal SCD events, the relative risk
for SCD in offspring was up to 9.4 [28].
Further, the role of modifier genes (gene–gene
interaction) is beginning to be appreciated.
Modifier genes are genes that are not involved
in the genesis of the disease but modify the sever-
ity of the phenotypic expression. The final pheno-
type is the result of interactions among causal
genes, modifier genes, and environmental factors.
Identification of modifier genes will complement the
results of studies of causative genes and could en-
hance genetic-based diagnosis, risk stratification,
and implementation of preventive and therapeutic
measures of SCD [31].
Post-myocardial infarction remodeling
and sudden cardiac death
Patients who suffer from a nonfatal MI as well
as those who survive SCD in the setting of acute
MI later undergo post-MI remodeling. Ventricular
remodeling is the process by which ventricular size,
shape and function are regulated by mechanical,
neurohormonal, and genetic factors [32–34]. Re-
modeling may be physiological and adaptive dur-
ing normal growth or pathological due to MI,
cardiomyopathy, hypertension, or valvular heart
disease. Post-MI remodeling is a complex time-
dependent process that involves structural, bio-
chemical, neurohormonal and electrophysiologic
alterations. The acute loss of myocardium results
in an abrupt increase in loading conditions that in-
duces a unique pattern of remodeling involving the
infarcted border zone and remote noninfarcted
myocardium [35]. Post-MI remodeling is associa-
ted with time-dependent dilatation, distortion of
ventricular shape, and hypertrophy of the non-
infarcted myocardium. Following a variable period
of compensatory hypertrophy, deterioration of con-
tractile function may develop resulting in conges-
tive heart failure.
In recent years the understanding of the sig-
nal transduction pathways for cardiac remodeling
in the post-MI heart [36, 37] has provided op-
portunities for novel therapeutic interventions.
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Figure 2 illustrates a proposed scheme for post-MI
signaling pathways [31]. Many of these pathways
were shown to be activated either in response to
ischemia/reperfusion stimuli or to a stretch stimu-
lus using different experimental models and some-
times non-cardiac cell systems. However, cell
membrane receptors and intracellular signaling pro-
teins are highly conserved between mammalian
species and the triggering events for cellular hyper-
trophy in humans are likely to resemble closely
those in the various animal models used. The dia-
gram shows that a cascade of successive transduc-
tion steps allows signal enhancement and diversi-
fication at branching points and thus permits com-
binatorial interactions between multiple pathways.
Although multiple signaling pathways may act in
synergistic, antagonistic, or permissive way some
key pathways may play a dominant role. There is
a plethora of experimental and clinical evidence
showing that the renin–angiotensin system and the
b-adrenergic system play major roles in post-MI
remodeling [34]. This explains the beneficial role
that angiotensin converting-enzyme inhibitors,
AT-1 receptor antagonists, and beta-blockers in the
post-MI period. More recently, other signaling path-
ways, for example, the calcineurin pathway [38] and
the Janus kinase/signal transducer and activator of
transcription (JAK-STAT) [39] signaling pathway
were also found to play a significant role in post-MI
remodeling. Pharmaceutical agents that can block
these pathways may provide new therapeutic mo-
dalities in the post-MI period.
Post-myocardial infarction remodeling
and electrophysiological vulnerability
A key electrophysiologic alteration in post-MI
remodeled heart is down regulation of K+ gene ex-
pression and K+ currents resulting in spatially he-
terogeneous prolongation of action potential dura-
tion and increased dispersion of refractoriness [40].
For many years the observation was made that car-
diac hypertrophy from whatever cause is consist-
ently associated with down regulation of K+ chan-
nel genes and K+ currents. However, recent stud-
ies have shown that, in the post-MI heart, this down
regulation occurs early and may be dissociated from
the slower time course of post-MI remodeled
hypertrophy [40]. It is therefore not surprising that
the post-MI heart is more sensitive to hypokalem-
ia and the proarrhythmic effects of drugs that de-
press K+ currents, especially Ikr blockers. Some
pharmacological interventions that have been
shown to reduce the incidence of SCD in post-MI
Figure 2. Post-myocardial infarction signaling pathways (modified from [34], with permission of Elsevier).
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patients, like magnesium [41] and spironolactone [42]
may act by countering the effects of low K+.
Sudden cardiac death and
systolic dysfunction
Although the exact mechanisms involved in the
strong correlation between decreased LV systolic
function and increased incidence of SCD are not
clearly defined, it is now recognized that one way
to combat SCD following MI is to try to halt or im-
prove the deterioration in LV function. The
mechanism(s) for the transition from compensated
to decompensated heart failure is under intensive
investigation and it is clear that multiple factors are
involved [43]. The role of continuous loss of cardi-
omyocytes to apoptosis in the noninfarcted myocar-
dium; the negative consequences of remodeling of
the interstitial matrix; the downregulation of the
b-adrenergic receptor-G protein-adenylyl cyclase
pathway; the downregulation of the L-type calcium
current, and the alterations in calcium regulated
excitation-contraction coupling are some of the
major mechanisms involved. Recent years have
seen significant advances in the treatment of ven-
tricular systolic dysfunction and heart failure. The
therapeutic armamentarium includes not only phar-
macological agents, but also electrical and surgical
devices. Besides the cornerstone drugs for heart
failure like digoxin, diuretics, angiotensin converting-
-enzyme inhibitors, and b-blockers, newer agents
like the aldosterone receptor antagonist spirono-
lactone, the endothelin antagonist bosentan, the va-
sopeptidase inhibitor omapatrilat, and the brain
natriuretic peptide (BNP) neseritide have been in-
vestigated in multicenter trials with varying results
[44]. BNP level was shown to be a strong predictor
of SCD in patients with chronic heart failure [45].
On the other hand, electrical devices like biven-
tricular pacing in selected groups of patients can im-
prove LVEF and mortality [46]. Further, surgical
procedures like passive external support have been
shown in experimental studies to reverse remode-
ling with reduced systolic wall stress and improved
adrenergic signaling [47]. The success of the LV
assist devices [48] has shown that even in an ad-
vanced stage of heart failure, the remodeling proc-
ess could be reversed with significant improvement
of ventricular function. Finally, clinical research has
demonstrated that gene transfer is a potential ther-
apeutic option to restore diseased cardiomyocytes
and rescue the failing heart [49].
Risk stratification of sudden
cardiac death in the post-myocardial
infarction period (Table 1)
In 2005, the Centers for Medicare and Medi-
caid Services (CMS) approved primary implantable
cardiac cardioverter defibrillator for patients in the
post-MI period who have LVEF of 35% and New
York Heart Association (NYHA) class II or III heart
failure [50]. These criteria were based on data from
MADIT II [51] and SCD-HeFT [52]. Implantation
is approved only after 40 days or more have elapsed
from the time of MI, on the basis of data from
DINAMIT [53]. One area of uncertainty of these cri-
teria is the unreliability of LVEF measurements as
well as evolution of LVEF over time and the way in
which this influences risk [54]. There is general
consensus that there is a need for more robust risk
stratification of SCD beyond LVEF.
All completed SCD primary ICD prophylaxis
trials addressed patients with one or more conven-
Table 1. Risk stratification of sudden cardiac death.
Electrophysiological surrogates Functional, biochemical, and genetic surrogates
Measures of conduction disorder: Funcional markers:
Signal averaged electrocardiogram, % of scar Left ventricular ejection fraction*
tissue in cardiac magnetic resonance
Measures of dispersion of repolarization: New York Heart Association class
QT dispersion, T-wave alternans
Measures of autonomic nervous system: Biochemical markers:
Direct: sympathetic nerve activity, 1231-MIBG scan C-reactive protein
Electrocardiogram-based: heart rate variability, Homocysteine level
baroreceptor sensitivity, heart rate turbulence, Serum matrix metalloproteinase
QT dynamicity Beta natriuretic peptide, etc.
Measures of altered calcium kinetics ??? Genetic markers ???
*Curently, left ventricular ejection fraction £ 35% is the main criterion for primary implantable cardioverter-defibrillator prophylaxis
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tional risk factors for SCD (Table 1) [31]. The elec-
trophysiological surrogates for SCD, including
measures of myocardial conduction disorders, dis-
persion of repolarization, and autonomic imbalance,
are based on sound scientific evidence. However,
the majority of conventional electrophysiological
risk stratifiers of SCD have a relatively low posi-
tive predictive value that would preclude their wide
application as guidelines for ICD implantation in
patients known to be at risk for SCD. This is not to
mention the impracticality of their use for risk strat-
ification in the general asymptomatic public. It is
not therefore surprising that the current main cri-
teria for SCD primary ICD prophylaxis are meas-
ures of ventricular dysfunction, i.e., LVEF and
NYHA class. There is general consensus that these
criteria may have strong predictive value for total
cardiac mortality but are not specific enough for
arrhythmic mortality. This explains the continued
effort to identify additional risk factors with inde-
pendent or additive predictive power for arrhyth-
mic death. These may include the use of newer tech-
niques of nuclear magnetic resonance with contrast
material to define anatomy of the infarct [55] as well
as possible future use of genetic risk profiling.
Conclusions
The immediate future goals for risk stratifica-
tion and management of SCD post-MI could be sum-
marized as follows:
1. Identification of novel clinical, biochemical, and
genetic markers for SCD and assessment of the
functional consequences of sequence variants
identified in human genetic studies as well as
relevant environmental-genetic interactions.
 2. Determination of the heritability of genetic risk
factors for SCD as well as the factors involved
in ethnic-specific differences in risk of SCD.
3. Identification of a battery of a relatively limi-
ted number of incrementally cumulative low-
intermediate risk variants and development of
a “signature” combination of clinical, bioche-
mical, and genetic markers of SCD. However,
we should not be surprised that the positive
predictive value of some of the new risk fac-
tors, similar to conventional risk factors, will
be relatively low, especially if these are applied
to large populations who are at low risk. In fact,
the true value of risk stratification of SCD in
the future may be to identify low-risk popula-
tions who do not warrant prophylactic interven-
tion with therapy that demonstrated efficacy,
e.g. the ICD.
4. Identification of novel pharmacological and
non-pharmacological approaches for risk mo-
dification and prevention of SCD. One exam-
ple is the interest in clinical prevention of SCD
by n-3 polyunsaturated fatty acids. Although
this relatively new diet-heart hypothesis that
underlies this therapeutic modality is yet to
catch the attention of the clinical community
at large, several experimental and clinical evi-
dence point to the validity of this approach [56].
5. Wider collaboration among different academic
and industrial institutions by sharing research
results as well as resources such as clinical
data, blood and other tissues from Bioreposi-
tory centers. The ultimate goal is not only to
change the current direction of management
strategy of SCD away from increased ICD uti-
lization, but primarily to identify novel methods
for risk stratification, risk modification, and
prevention of SCD that could be applied to the
general public at large.
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